Zug, Switzerland, April 23, 2025 – Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced that all proposals of the Board of Directors at its first Annual General Meeting (AGM), held via live webcast, were approved by shareholders by a large majority. This includes the payment of a gross dividend of 0.15 CHF per dividend-bearing share^[1], to be distributed out of reserves from capital contributions.

Shareholders reelected all members of Board of Directors, including Thomas Ebeling (Chair), Dr. Flemming Ørnskov, Michael Bauer, Marcus Brennecke, Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, and Sherilyn McCoy. In addition, Roberto Marques was newly elected to the Board. 

The AGM also approved the company’s 2024 Annual Financial Statements, Non-Financial Report, and Compensation Report.

Detailed voting results and the official minutes will be published on Galderma's Investor Relations website (https://investors.galderma.com) within the next two weeks. 

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

For further information: